Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Selina J Chavda, MBBS, BSc, MRCP, Rachael Pocock, MBBS, BSc, MRCP, Simon Cheesman, BPharm, Emma Dowling, Puneet Verma, MRPharmS, Malcolm Walker, MBBS, MBChB, MD FRCP, Charalampia Kyriakou, MD PhD, Ashutosh D. Wechalekar, Neil K Rabin, MD, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2018-99-113832

Published: 2018

Journal Articles

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Joanne Sowter, MSc, Dimitrios A Koutoukidis, PhD, Maggie Heinrich, PhD, Orla McCourt, MSc, Allan Hackshaw, Rebecca Beeken, PhD, Dunnya De-Silva, Stephanie Philpott, MSc, Ali Rismani, MBBS, Neil K Rabin, MD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Atul Mehta, FRCP, Bruce Paton, PhD, Abigail Fisher, PhD, Kwee Yong, PhD

Blood (2018) 132 (Supplement 1): 974.

https://doi.org/10.1182/blood-2018-99-111403

Published: 2018

Journal Articles

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Jenny O'Nions, MBBChir, PhD MRCP, FRCPath, Anna Cowley, MBBS, BSc, MRCP, FRCPath, Hakim-Moulay Dehbi, PhD, Dima El-Sharkawi, MBBS BSc FRCPath MD, Shirley D'Sa, MD FRCP, FRCPath, Kirit M. Ardeshna, MA MDFRCP FRCPath, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, William Townsend, MD FRCPath

Blood (2018) 132 (Supplement 1): 4227.

https://doi.org/10.1182/blood-2018-99-118497

Published: 2018

Journal Articles

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Anna Cowley, MBBS, BSc, MRCP, FRCPath, Jenny O'Nions, MBBChir, PhD MRCP, FRCPath, Hakim-Moulay Dehbi, PhD, Dima El-Sharkawi, MBBS BSc FRCPath MD, William Townsend, MD FRCPath, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2018-99-118706

Published: 2018

Journal Articles

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Rakesh Popat, MBBS, PhD, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, MBBS, FRPATH, MRCP, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Kwee L Yong, MBChB, PhD, Gordon Cook, MD PhD, James D. Cavenagh, MD

Blood (2015) 126 (23): 1826.

https://doi.org/10.1182/blood.V126.23.1826.1826

Published: 2015

Journal Articles

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Arash Latifoltojar, MB BS, MSc, MPhil, Kwee L Yong, MBChB, PhD, Margaret Hall-Craggs, BA, MB BS, MD, Neil Rabin, MB,BS, PhD, Rakesh Popat, MBBS, PhD, Alan Bainbridge, Magdalena Sokolska, Nikolaos Dikaios, Shirley D'Sa, MD FRCP, FRCPath, Ali Rismani, MBBS, Shonit Punwani, Mb BS, BSc, PhD

Blood (2015) 126 (23): 1850.

https://doi.org/10.1182/blood.V126.23.1850.1850

Published: 2015

Journal Articles

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Rakesh Popat, MBBS, Heather E. Oakervee, MRCPath, Nicola Curry, MBBS, Nicola Foot, BSc, Curly Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David Schenkein, MD, Dixie-Lee Esseltine, MD, Jamie D. Cavenagh, MD

Blood (2005) 106 (11): 2554.

https://doi.org/10.1182/blood.V106.11.2554.2554

Published: 2005

NARROW

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only